Jennifer Beane <\/a>(ENG\u201907), the lead and corresponding author of the Nature Communications<\/i> study, and a Boston University School of Medicine assistant professor of computational medicine.<\/p>\nThe new findings have identified four different genomic subtypes among current and former cigarette smokers who develop precancerous lesions. In people with the most problematic subtype, their immune response is impaired, says Spira, a BU School of Medicine professor of medicine, pathology, and bioinformatics and the Alexander Graham Bell Professor in Health Care Entrepreneurship.<\/p>\n
\u201cThat\u2019s one of the things that tumors do\u2014prevent the immune system from attacking them. We think precancer cells might do that as well,\u201d Spira says. \u201cThis opens up the opportunity to come in and find a way to train the immune system to eradicate those lesions.\u201d<\/p>\n
Any drug that could arrest or prevent lung cancer from developing in smokers would be the first of its kind. \u201cThere is nothing [for lung cancer] like there is aspirin for colorectal cancer or statins for cardiovascular disease,\u201d he says.<\/p>\n
In the study, Beane, Spira, and other scientists at MED, the University of California, Los Angeles, the Roswell Park Comprehensive Cancer Center, in Buffalo, N.Y., and Janssen Research & Development used bronchoscopes to take biopsies of precancerous lung lesions in current and former smokers, following the study participants over several years to see if their lesions progressed toward lung cancer or not. They identified biological changes within the lesions that indicated a higher risk of progression and showed that those lesions had reduced activity of genes related to certain kinds of immune cells.<\/p>\n
\u201cThis is an example where academia does the very basic discovery science\u2014finding patients that have these early precancer lesions, biopsying them, and doing very deep molecular profiling, and the bioinformatics analysis,\u201d says Spira. Then, from those academic findings, \u201cindustry can look at the data and figure out how to develop a therapeutic that will leverage that insight, that would reactivate the immune system to intercept the precancerous lesions from progressing to invasive lung cancer.\u201d<\/p>\n
In addition to its other findings, the new study suggests that changes in aggressive precancerous lesions could be detected by \u201cbrushing,\u201d using a flexible brush to gather cells from the airway through the catheter of a bronchoscope, which is a much less invasive procedure than a traditional lung or airway biopsy.<\/p>\n
\u201cNormal-appearing cells in the airway can still show you the genomic signature,\u201d says Beane. \u201cIt\u2019s early days, but maybe one day [we] could develop a simpler test to find someone who is incubating a lung cancer and [we\u2019d] know who to treat to intercept lung cancer.\u201d<\/p>\n
The PCGA was developed by Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and BU. It has received additional funding from Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team, the National Cancer Institute, and the new Translational Research Alliance between BU and the Lung Cancer Initiative at J&J.<\/p>\n
This study was supported in part by the National Cancer Institute, National Institutes of Health; the National Heart, Lung, and Blood Institute, National Institutes of Health; Stand Up To Cancer, LUNGevity, American Lung Association Lung Force; and Janssen Research & Development, LLC.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Tuesday, April 23, 2019 Source: BU Today In this microscopic image of precancerous lung tissue, the hot pink cells are dividing faster than in normal lung tissue. Credit: Beane, et al., Nature Communications Genomic differences related to the immune system may play a key role in the early development of lung cancer. That finding, published […]<\/p>\n","protected":false},"author":16142,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[10,7],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2464"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/users\/16142"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/comments?post=2464"}],"version-history":[{"count":3,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2464\/revisions"}],"predecessor-version":[{"id":2468,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2464\/revisions\/2468"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/media?parent=2464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/categories?post=2464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/tags?post=2464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"In](\"https:\/\/www.bu.edu\/today\/files\/2019\/04\/beane.png\")
<\/p>\n